Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor

93Citations
Citations of this article
162Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Genetically modified T cells to recognize tumor-associated antigens by transgenic TCRs or chimeric antigen receptors (CAR) have been successfully applied in clinical trials. However, the disadvantages of either TCR mismatching or the requirement of a surface tumor antigen limit their wider applications in adoptive T cell therapy. A TCR-like chimeric receptor, specific for the melanoma-related gp100/HLA-A2 complex was created by joining a TCR-like antibody GPA7 with the endodomains of CD28 and CD3-ζ chain. This TCR-like CAR, GPA7-28z, was subsequently introduced into human T cells. Retargeted T cells expressing GPA7-28z could exhibit efficient cytotoxic activities against human melanoma cells in vitro in the context with HLA-A2. Furthermore, infusion of GPA7-28z-transduced T cells suppressed melanoma progression in a xenograft mouse model. Redirecting human T cells with TCR-like CARs would be a promising alternative approach to TCR-mediated therapy for melanoma patients, which is also feasible for targeting a variety of other tumor antigens.

Cite

CITATION STYLE

APA

Zhang, G., Wang, L., Cui, H., Wang, X., Zhang, G., Ma, J., … Gao, B. (2014). Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor. Scientific Reports, 4(SREP03571). https://doi.org/10.1038/srep03571

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free